However, the variable results concerning serum and muscle myostatin levels and loss of muscle mass in humans apparently rule out a major role for this signaling pathway [25], despite the evidence of sarcopenia decrease following myostatin inhibition in animal investigations [34]. Here, MSTN is linked to sarcopenia.